Zeraatkar Dena, Pitre Tyler, Leung Gareth, Cusano Ellen, Agarwal Arnav, Khalid Faran, Escamilla Zaira, Cooper Matthew Adam, Ghadimi Maryam, Wang Ying, Verdugo-Paiva Francisca, Rada Gabriel, Kum Elena, Qasim Anila, Bartoszko Jessica Julia, Siemieniuk Reed Alexander Cunningham, Patel Chirag, Guyatt Gordon, Brignardello-Petersen Romina
Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
McMaster University, Hamilton, ON, Canada.
BMJ Med. 2022 Oct 3;1(1):e000309. doi: 10.1136/bmjmed-2022-000309. eCollection 2022.
To assess the trustworthiness (ie, complete and consistent reporting of key methods and results between preprint and published trial reports) and impact (ie, effects of preprints on meta-analytic estimates and the certainty of evidence) of preprint trial reports during the covid-19 pandemic.
Retrospective review.
World Health Organization covid-19 database and the Living Overview of the Evidence (L-OVE) covid-19 platform by the Epistemonikos Foundation (up to 3 August 2021).
Comparison of characteristics of covid-19 trials with and without preprints, estimates of time to publication of covid-19 preprints, and description of differences in reporting of key methods and results between preprints and their later publications. For the effects of eight treatments on mortality and mechanical ventilation, the study comprised meta-analyses including preprints and excluding preprints at one, three, and six months after the first trial addressing the treatment became available either as a preprint or publication (120 meta-analyses in total, 60 of which included preprints and 60 of which excluded preprints) and assessed the certainty of evidence using the GRADE framework.
Of 356 trials included in the study, 101 were only available as preprints, 181 as journal publications, and 74 as preprints first and subsequently published in journals. The median time to publication of preprints was about six months. Key methods and results showed few important differences between trial preprints and their subsequent published reports. Apart from two (3.3%) of 60 comparisons, point estimates were consistent between meta-analyses including preprints versus those excluding preprints as to whether they indicated benefit, no appreciable effect, or harm. For nine (15%) of 60 comparisons, the rating of the certainty of evidence was different when preprints were included versus being excluded-the certainty of evidence including preprints was higher in four comparisons and lower in five comparisons.
No compelling evidence indicates that preprints provide results that are inconsistent with published papers. Preprints remain the only source of findings of many trials for several months-an unsuitable length of time in a health emergency that is not conducive to treating patients with timely evidence. The inclusion of preprints could affect the results of meta-analyses and the certainty of evidence. Evidence users should be encouraged to consider data from preprints.
评估2019冠状病毒病大流行期间预印本试验报告的可信度(即预印本与已发表试验报告之间关键方法和结果的完整且一致的报告情况)及影响(即预印本对荟萃分析估计值和证据确定性的影响)。
回顾性审查。
世界卫生组织2019冠状病毒病数据库以及Epistemonikos基金会的“证据动态概述”(L-OVE)2019冠状病毒病平台(截至2021年8月3日)。
比较有预印本和无预印本的2019冠状病毒病试验的特征、2019冠状病毒病预印本的发表时间估计,以及描述预印本与其后续发表报告在关键方法和结果报告方面的差异。对于八种治疗方法对死亡率和机械通气的影响,该研究包括荟萃分析,在针对该治疗的首个试验以预印本或发表形式可得后的1个月、3个月和6个月,分别纳入预印本和排除预印本进行分析(总共120项荟萃分析,其中60项纳入预印本,60项排除预印本),并使用GRADE框架评估证据的确定性。
在该研究纳入的356项试验中,101项仅以预印本形式可得,181项以期刊发表形式可得,74项先以预印本形式出现,随后发表在期刊上。预印本的中位发表时间约为6个月。试验预印本与其后续发表报告在关键方法和结果方面几乎没有重要差异。在60项比较中,除了2项(3.3%),关于是否显示有益、无明显效果或有害,纳入预印本的荟萃分析与排除预印本者的点估计值是一致的。在60项比较中的9项(15%)中,纳入预印本与排除预印本时证据确定性的评级有所不同——纳入预印本时证据确定性在4项比较中更高,在5项比较中更低。
没有确凿证据表明预印本提供的结果与已发表论文不一致。在几个月内,预印本仍是许多试验结果的唯一来源——在卫生紧急情况下,这一时长不合适且不利于及时为患者治疗提供证据。纳入预印本可能会影响荟萃分析的结果和证据的确定性。应鼓励证据使用者考虑预印本数据。